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Summary 
The role of autoantigens and that of target organs in which tissue lesions develop remains elusive 
in most spontaneous models of autoimmune diseases.  Whether  the presence of target autoan- 
tigens is required for the recruitment  of autoreactive lymphocytes is unknown  in most cases. 
To evaluate  the importance of islet cells in the development of autoimmunity in the nonobese 
diabetic (NOD) mouse, we generated/3 cell-deprived mice by injecting a high dose of alloxan, 
a toxic agent specific for/5 cells. In contrast with spleen cells from 6-mo-old naive  NOD mice 
which transfer diabetes in irradiated  8-mo-old male recipients,  spleen cells from age-matched 
NOD mice which received a single injection of alloxan at 3 wk of age did not transfer diabetes. 
With the exception of the ability to transfer diabetes,/3 cell-deprived NOD mice showed main- 
tained immune competence. Furthermore,  sialitis developed with the expected intensity and prev- 
alence in/3  cell-deprived mice.  Already committed "diabetogenic" spleen cells collected from 
spontaneously diabetic mice also showed a reduced capacity to transfer diabetes after their removal 
from the diabetic mice and transient  "parking"  in/3 cell-deprived mice.  Taken  together,  our 
data bring evidence that involvement of autoreactive T cells detected by the capacity to transfer 
diabetes requires  the presence of target/3  cells. 
T 
he role of antigens in events responsible for the break 
down of self tolerance is poorly defined in most sponta- 
neous models of autoimmune  diseases.  Whether  the pres- 
ence of target autoantigens is required for initiating and main- 
taining immune reponses responsible for the development of 
autoimmune  diseases  is a fundamental  question.  A  related 
issue is whether antigen presentation and the initial activa- 
tion of autoreactive lymphocytes takes place at the target organ 
site or within a distant site. Evidence for both local and dis- 
tant priming and expansion is inferred from experimentally 
induced autoimmune models. In models in which autoim- 
munity is triggered by immunization against syngeneic tissues 
and antigens in CFA, the priming event is distant from the 
site in which the target autoantigen is expressed (1, 2). Simi- 
larly,  in transgenic mice expressing a viral protein on target 
cells,  autoimmunity develops after systemic infection with 
the complete virus, likely as a collateral effect of T cell stimu- 
lation occurring outside the target organ (3, 4). The same 
hypothesis holds in the case of molecular mimicry due to 
shared antigenic determinants between autoantigens and ex- 
ternal  antigens  (5-7).  However, events taking  place at the 
site of target tissues,  such as abnormal antigen expression or 
the local production of cytokines, have been evidenced as ini- 
tiating  autoimmunity  in other models (8-11). 
The nonobese diabetic (NOD) 1 mouse is a relevant  model 
1  Abbreviation used in this paper: NOD, nonobese diabetic. 
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tO address the role of autoantigen in the development of spon- 
taneous autoimmune diseases. The NOD mouse develops in- 
sulitis and diabetes along with other organ infiltrations, par- 
ticularly sialitis  (12, 13). The predominant role of T cells in 
this model is indicated by the predominance of T cells within 
the islet infiltrate  (14,  15),  by the transfer  of diabetes into 
syngeneic recipients by purified T cells from diabetic and non- 
diabetic mice older than 4 mo of age (16,  17),  and by the 
prevention of diabetes after the injection of mAbs to CD4 
T  cells  and APCs (18-20). 
To evaluate the importance of islet insulin-secreting/3 cells 
in the development of autoimmunity in the NOD mouse, 
we generated/3 cell-deprived mice in which we studied the 
differentiation  of cells  tranferring  diabetes in conventional 
NOD recipients, the extent of sialitis,  and the recurrence of 
insulitis in syngeneic islet grafts.  We used/3 cell-deprived 
mice as recipients  of spleen cells from diabetic animals  to 
evaluate the outcome of cells transferring  diabetes in the absence 
of autoantigen-expressing  cells. 
Materials and Methods 
Mice.  NOD mice were bred  in  our facilities under  specific 
pathogen-free conditions and checked every 6 mo for bacterial, viral, 
and parasitic infections. The spontaneous incidence of diabetes in 
our colony is 75% in females and 40% in males at 6 mo of age. 
Mice were monitored for glucosuria (Glucotest; Boehringer Mann- 
heim, Mannheim, Germany) twice a week. Glucosuric mice were 
tested for glycemia by retroorbitar  sinus venous puncture  using 
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F; Boehringer Mannheim). Diabetes  was diagnosed as persistent 
glycemia >3.5  g/liter. 
Alloxan.  Alloxan (Sigma Chemical Co., St. Louis, MO) was 
administered  by an injection of 150 mg/kg i.v. at weaning or as 
stated (21). Diabetic mice were treated by daily subcutaneous lente 
insulin injection (Ultratard; Novo, Bagsvaerd, Denmark). Insulin 
dosage was modulated according to weight, ranging from 0.5 to 
2 U/d. 
Histology.  Frozen sections of pancreas 5-#m-thick, with at least 
five levels separated by 120 #m, were stained with hemalun (Merck, 
Darmstadt, Germany) and eosin. Immunohistochemistry was per- 
formed with streptavidin-biotin-horseradish peroxidase (Amersham 
International, Amersham, Bucks, UK), and Diaminobenzidine as 
a substrate  (Sigma Chemical Co.) using anti-insulin (monoclonal 
guinea  pig  anti-swine;  Dako,  Glostrup,  Denmark)  and  anti- 
synaptophysin antibodies (polyclonal rabbit anti-human, Dako) (22). 
Second antibody was either biotinylated goat anti-guinea pig anti- 
body (Jackson ImmunoResearch Labs., Inc., West Grove, PA) or 
biotinylated goat anti-rabbit antibody (Jackson ImmunoResearch). 
Frozen sections of submandibular glands, 7-/~m-thick, with at 
least five sections per gland separated by 100/~m, were stained with 
hematein and eosin, and evaluated blindly by two independent ob- 
servers with a grid ocular. On each section were evaluated the sur- 
face ofsero-mucous parenchyma, the number of  infiltrates, and the 
individual surface of the infiltrates.  Results were expressed as the 
number of infiltrates  per 100 squares of sero-mucous  tissue, and 
the ratio surface of infiltrate divided by the surface of sero-mucous 
parenchyma x  100. Concordance of independent readings was es- 
timated by the interclass correlation coefficient and was found to 
be >0.94. 
Adoptive  Transfer of Diabetes.  Diabetes  was transferred  as de- 
scribed by Wicker et al. (16). 8-wk-old male NOD recipients were 
first irradiated (750 tad) and then injected intravenously with 107 
spleen ceils prepared aseptically in HBSS collected from f-too-old 
alloxan-treated  or control mice. 
Cotransfer of Diabetes.  Cotransfer of diabetes was performed as 
previously described (23). 8-wk-old, irradiated, male NOD recipients 
were injected intravenously with 2  x  107 spleen cells collected 
from 6-mo-old  alloxan-treated  mice,  and  24  h  later,  with  107 
spleen cells collected  from diabetic  NOD  mice. 
Serial Transfer.  Splenocytes from diabetic NOD females were 
transferred  into  irradiated,  8-wk-old,  normal  (controls)  or  /3 
cell-deprived NOD males (first order recipients).  14 d later, first 
order recipients served as donors of spleen cells for a second order 
transfer into similar preirradiated normal or 3 cell-deprived NOD 
males.  At  each  transfer  step,  spleen  cells  from  control  or  3 
cell-deprived  recipients were tested for their capacity to transfer 
diabetes into conventional, preirradiated,  non ~ cell-deprived male 
NOD recipients, as referred to above (adoptive transfer of diabetes). 
Anti-human Insulin Antibodies.  Anti-human insulin antibodies 
were detected as described by Palmer et al. (24), by precipitation 
ofiodinated tracer insulin. Results were expressed as percent precipi- 
tation of the tracer. 
GVHD.  (NODxC57BL/6)F1 newborn mice received an in- 
traperitoneal  injection of 107  splenocytes  from /3  cell-deprived 
NOD mice. Recipients were killed 10 d later. Spleen weight ratio 
to body weight was measured, and a spleen enlargement index was 
calculated by dividing the relative spleen weight of experimental 
animals by the relative spleen weight of littermate controls.  The 
index was considered  positive  above 1.3 (25). 
Islets Grafting.  Islets of Langerhans were isolated from 6-wk- 
old NOD male mice as described by Lacy and Kostianovsky (26) 
with modifications. Briefly,  islets were digested for 6 rain in 4 mg/ml 
collagenase P (Boehringer Mannheim) in PBS, by shaking at 37~ 
and washed in PBS. They were then poured on a discontinuous 
Ficoll gradient (Sigma  Chemical Co.).  After centrifugation for 
20 rain at 800 g, islets were collected, washed in PBS, and further 
purified by hand-picking under a microscope. Islets were cultured 
for 7 d under 5% CO2 at 37~  in MEM (Gibco, Paisley, UK), 
5.5 mM glucose, supplemented with 5% FCS, penicillin, and strep- 
tomycin. Mice were anesthesized  with Avertin  (2.2.2-Tribromo- 
methanol; Aldrich-Chimie,  Strasbourg, France). Islets were grafted 
under the left kidney capsule as described by Ricordi and Lacy (27). 
StatisticalAnalysis.  Statistical analysis was performed using Stu- 
dent's t test and X  2 analysis. 
Results 
Characterization  of fl  Cell-deprived  NOD  Mice.  Female 
NOD mice deprived of 3 cells were prepared by performing 
a single injection of 150 mg/kg of aUoxan at the age of 3 
wk, i.e., before any detection of islet infiltration by macro- 
phages  and T  cells. These mice were first characterized as 
for the absence of~ cells. They developed severe diabetes within 
24 h  after aUoxan injection and were kept alive by a daily 
subcutaneous insulin injection. On  histological sections of 
pancreata collected at 6 mo of age, islets were scarce or replaced 
by extensive scars. Only a few small remnant islets could be 
detected that contained cells staining for synaptophysin, a 
marker  of  secretory  granules  of  endocrine  cells  (mostly 
glucagon and somatostatin), but no insulin-containing cells 
were detected. However, few sites of inflammatory cells were 
detected in the vascular spaces and in the vicinity of remnant 
islets. No invasive infiltration with lymphocytes within remant 
islets was seen (Fig.  1). 
To first evaluate the importance of B cells in allowing the 
expansion of"diabetogenic" T cells defined by their capacity 
to transfer diabetes into syngeneic recipients, we tested the 
capacity of spleen cells from 6-too-old B cell-deprived donors 
to transfer diabetes.  As shown in Fig.  2,  spleen cells from 
/3 cell-deprived NOD mice failed to transfer diabetes. None 
of the preirradiated male recipients had developed diabetes 
by 12 wk after transfer, as opposed to 89% of recipients of 
spleen cells from untreated, age-matched, controls. Effector 
T cells detected by diabetes transfer thus did not differentiate 
or expand enough to transfer diabetes in the absence of 3 cells. 
As alloxan-mediated massive release of pancreatic 3  cell 
antigens at the age of 3 wk in NOD female mice might in- 
Figure 1.  Islet  and salivary gland histology in alloxan-treated  NOD mice. (a-c) Pancreas and salivary gland histology in 6-mo-old NOD females 
that received a single injection of 150 mg/kg alloxan  at 3 wk of age. (a and b ) the same islet of Langerhans  on serial sections stained  with (a) antisynap- 
tophysin and (b) anti-insulin (original x128). (c) Islet graft infiltration 14 wk after grafting (hematoxylin-eosin  staining, original x 128). (d) Sialadenitis 
(hematoxylin-eosin staining, original x51). 
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Figure 2.  Incidence  of adoptive  transfer  of diabetes from  alloxan-treated 
mice. Nondiabetic  and B cell-deprived  donors were injected  with buffer 
(PBS) or alloxan (150 mg/kg) as a single intravenous  injection  at 3 wk 
of age. 8-wk-old, preirradiated  (750 rad), male  recipients  received  an intra- 
venous infusion  of 107 spleen cells from naive nondiabetic  (O, n = 29) 
or 3 cell-deprived (e, n =  18) 6-mo-old female donors. 
duce regulatory T cells, a cotransfer experiment was performed 
to evaluate the induction of  regulatory T cells in ~ cell-deprived 
mice. The transfer of diabetes by spleen cells from spontane- 
ously diabetic  animals was  actually not  inhibited by the 
cotransfer of spleen cells from 6 mo-old mice pretreated with 
alloxan at the age of 3 wk (Fig.  3).  It is thus unlikely that 
alloxan induced active  suppression  when injected in 3 wk- 
old NOD  female mice. 
The competence of the immune system of/3 cell-deprived, 
insulin-treated animals was evaluated. The evaluation of lym- 
phocyte subsets showed no significant change in alloxan-treated 
mice. The percentage of B, T, CD4 +, and CD8 + cells was 
respectively 31.7  _+ 4.4, 52.3  __+ 8.9, 36.9  __ 4.5, and 8.8  __ 
3.6 (n  --  18) in alloxan-treated mice; 31.3  __  4.3, 46.0  _+ 
8.5, 30.6  _+  3.6, and 12.1  __+  3.9 (n  =  7) in control mice 
at 6 mo of age. No significant difference in the absolute number 
of the various lymphocyte subsets  was seen in these mice. 
We investigated the ability of mice to respond to a foreign 
protein. At the age of 6 mo, all insulin-treated diabetic mice 
had high levels of anti-human insulin antibodies: 32.9  _+ 
14.4% (n  =  6) precipitation of radiolabeled  insulin tracer, 
versus 51.3 _+  7.5% (n =  6) for spontaneously diabetic NOD 
mice treated by insulin for 6 wk. Three/3 cell-deprived mice 
were also evaluated by testing the ability of their splenocytes 
to develop GVH response in (NOD x C57BL/6)F1  recipients. 
10 d after the injection of NOD splenocytes in F1 neonates, 
spleen index ratios were comparable to controls: 3.7,  3.8, 
and 4.0 for/3 cell-deprived animals, and 4.1 for an untreated 
diabetic female. 
Sialitis  in fl Cell-deprived NOD  Mice.  A remarkable,  al- 
though still unexplained, feature of the NOD mouse disease 
is, beyond the development of anti-/3 cell autoimmunity, that 
of other target tissue infiltrates.  We took advantage of B 
cell-deprived NOD mice to ascertain  the role of islet cells 
in the development of sialitis within salivary glands. Sialitis 
developed in all ~/cell-deprived mice to an extent that was 
comparable to that of control animals (Table 1). The inten- 
sity of sialitis suggests that islet cells are not required in the 
development of sialitis and brings further evidence that im- 
mune competence is maintained in fl cell-deprived NOD mice. 
Serial Transfer of Diabetogenic Spleen Cells in fl Cell-deprived 
Recipients,  To ascertain the importance of persisting islet 
cells in maintaining T  cells from diabetic animals in a di- 
abetogenic functional state, T cells from diabetic mice were 
removed from their diabetogenic environment and "parked" 
in/3 cell-deprived adoptive hosts before their transfer in con- 
ventional recipients. We thus performed serial adoptive transfers 
of spleen cells from spontaneously diabetic donors into ir- 
radiated 8-wk-old male, control or ~  cell-deprived hosts. 
After one and two consecutive 14-d passages in control 
or/3 cell-deprived recipients, spleen cells were transferred into 
conventional, preirradiated recipients to evaluate their func- 
tional state (Fig. 4). The incidence of  diabetes transfer by spleen 
cells from spontaneously diabetic donors was 75%. When 
the same spleen cells from diabetic donors were parked once 
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Figure 3.  Cotransfer  of diabetes. 
Incidence of diabetes in irradiated 
(750 tad) 8 wk-old  male  NOD mice 
used as recipients of 2 x 107 spleen 
cells from  6-mo-old  B  cell-deprived 
NOD mice  that  received  150 mg/kg 
alloxan at 3 wk of age, plus 107 
spleen cells collected  from sponta- 
neously  diabetic  mice (open symbols, 
n  =  14), 107  spleen cells from 
spontaneously  diabetic mice alone 
(closed symbols, n =  15), and 107 
spleen cells from ~ cell-deprived 
mice alone (diamonds, n = 8). Table  1.  Sialadenitis in NOD Mice at the Age of 6 Mo 
Number  Surface 
Alloxan (n  =  6)  1.6  +  0.6  3.8  _+  2.4 
Controls  (n  =  4)  1.2  _+  0.4*  1.8  +_ 0.8* 
Results are expressed as number of mononuclear  cell infiltrates  per 100 
squares of serous tissue (Number) and surface  of infiltrate  divided  by the 
surface of serous tissue x  100 (Surface). Results are expressed as mean 
-+  SD. 
*/0  =  Nonsignificant  vs alloxan (Student's t test). 
or twice for 14 d in preirradiated 8-wk-old controls with a 
normal/5 cell mass, the efficiency of transfer was maintained 
(62.5 and 60%, respectively).  In contrast, when spleen cells 
were parked into irradiated, alloxan-treated, 3  cell-deprived 
8-wk-old  hosts,  the efficiency  of transfer in  conventional 
recipients fell to 40% after one passage and to zero after the 
second passage  (Fig.  4).  A  toxic effect of alloxan was not 
responsible  for the decreased  transfer efficiency, as demon- 
strated by the 100%  prevalence  of diabetes  in recipients of 
spleen cells from spontaneously diabetic NOD mice that had 
received a single injection of 150 mg/kg of alloxan 8 d before 
transfer.  Similarly,  insulin treatment or hyperglycemia did 
not reduce the efficiency of transfer when spleen cells from 
diabetic donors were parked into spontaneously diabetic,  ir- 
radiated, NOD recipients treated or not treated, respectively 
with insulin for the same duration (data not shown). 
Recurrence of  lnsulitis  on Syngeneic  Islet Grafts.  The impor- 
tance of/3 cells in allowing the development and the main- 
tainance of diabetogenic T  cells does not imply that target 
/3 cells are necessary for the initial priming of autoreactive 
T  cells rather than the maintenance of already committed 
cells in a diabetogenic state. To address this issue, we studied 
the infiltration of syngeneic islets grafted under the kidney 
capsule  of 3  cell-deprived NOD  mice. 
Precultured syngeneic islets were grafted under the kidney 
capsule of six 6-mo-old NOD mice treated with alloxan at 
3 wk of age. Normoglycemia  was achieved 48 h after grafting. 
Five mice were still normoglycemic 14 wk later.  The grafts 
were, however,  heavily infiltrated by lymphocytes (Fig.  1). 
One mouse had an early (7 wk) nonimmune-mediated graft 
failure.  The absence of diabetes  14 wk after islet grafting, 
and the slow recurrence of insulitis in grafted islets suggest 
that the whole autoimmune process had to start de novo after 
grafting, indicating that autoreactive T  cells remained un- 
primed after early aUoxan treatment, independently of the 
development of sialadenitis  and exocrine pancreatic infiltra- 
tion. This is in contrast with the outcome of grafts in three 
spontaneously diabetic control mice in which diabetes recurred 
within 4  to 7 d. 
Discussion 
Following the pioneering demonstration that immunolog- 
ical self-tolerance is an acquired phenomenon (28,  29),  evi- 
dence has accumulated for the direct role of antigens in eliciting 
and maintaining immunological tolerance.  The presence of 
antigen is central in driving both deletional and nondeletional 
mechanisms of tolerance (30-35).  The absence  or the loss 
of autoantigen may lead to deficient self-tolerance  in vivo 
(36-38).  In autoimmune diseases however,  the need for the 
presence and presentation of self-antigens in mechanisms al- 
lowing the breakdown of self-tolerance  and the activation 
and expansion of autoreactive T cells remains unclear. There 
has been scarce evidence  suggesting that autoimmune dis- 
eases may directly follow primary immune abnormalities and 
develop independently of the presentation of autoantigen. In- 
trinsic immune defects occurring independently of target au- 
toantigens are directly responsible  for autoimmune diseases 
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Figure 4.  Serial  adoptive  transfer 
of diabetes. Prevalence of diabetes 
in recipients  of  spleen  cells.  Ten mil- 
lion splenocytes  from  spontaneously 
diabetic  NOD mice  were  trans~rred 
into preirradiated (750 red) 8-wk- 
old male  NOD mice, treated  or not 
by a single  intravenous  injection  of 
alloxan  7 d before. A second  round 
of adoptive transfer of splenocytes 
was performed  in the same condi- 
tions 14 d later. The prevalence of 
diabetes was studied, at all stages, 
in preirradiated 8-wk-old male re- 
cipients of splenocytes. observed in immunoproliferative disorders in humans  (39). 
Susceptibility genes may directly alter major immune func- 
tion as in systemic lupus syndromes associated with the lpr 
or the gld mutations in the mouse, and in recently developed 
transgenic mice expressing autoreactive B or T  cell antigen 
receptors or Bcl-2 (40-44).  In diabetes,  as in most sponta- 
neous autoimmune diseases, it is likely that intrinsic immune 
defects related to the selection or expansion of the B or T 
cell repertoire or with abnormalities  of immune regulation 
(45) are only part of a multifactorial process that also involves 
environmental triggering events and possibly target tissues. 
Whether the first activation of autoreactive lymphocytes in- 
volves the direct recognition  of target  cell autoantigens  or 
that of antigens sharing cross-reactive epitopes with target 
antigens remains an open issue.  Both cases have been made 
in transgenic mice in which diabetes has followed the sys- 
temic presentation of virus expressing an antigen expressed 
on/3 cells as a transgene (3, 4) or the activation of autoreac- 
tive T  cells by local production  of cytokines after targeted 
cytokine transgene  expression (9-11). 
Our data point to the requirement  for the presence of/5 
cells in  the activation  of islet-specific T  cells in the NOD 
mouse. After a single injection of a high dose of alloxan be- 
fore any detectable infiltration  of the islets by macrophages 
and lymphocytes,  NOD  mice showed no expansion of di- 
abetogenic T  cells as evidenced by the failure of spleen cells 
from 6 mo old,/5 cell-deprived, NOD mice to transfer dia- 
betes in irradiated recipients. Spleen cells from alloxan-treated 
mice did not suppress the transfer of diabetes by spleen cells 
from  spontaneously  diabetic  animals,  as  indicated  by the 
cotransfer experiment.  Tolerized T  cells able to downregu- 
late diabetogenic T cells were thus not detectable in alloxan- 
treated animals.  In contrast with established models of im- 
mune/5 cell destruction after repeated injections of low doses 
of streptozotocin, alloxan has never been reported to induce 
insulitis,  including in the case of repeated low-dose injections 
(46).  Massive doses were chosen to preclude remissions of 
diabetes which have been reported  to occur when  two- to 
threefold lower doses were used (21).  Islets were actually 
scarcely seen on pancreatic  sections from/5 cell-deprived mice, 
and no/5 cells were detected in remnant islets.  Importantly, 
sialitis developed with the expected intensity and prevalence 
in alloxan-treated  mice,  indicating  that  immune  responses 
directed against non B-cell related tissues were maintained 
in alloxan-treated mice.  This also indicates  that  sialitis  de- 
velops independently  of 3  cells.  The absence of detectable 
expansion of/5 cell-reactive T  cells in alloxan-treated  mice 
brings direct evidence that autoantigens that trigger the anti- 
islet immune reaction are not expressed or presented in sali- 
vary glands, as previously supported by a dissociation of in- 
sulitis and  sialitis  development in  transgenic  mice (47). 
￿9 Serial transfer experiments in which spleen cells from dia- 
betic animals  were parked in irradiated  control or aUoxan- 
treated,/5 cell-deprived, transient recipients also indicates that 
the presence of/5 cells was required to maintain diabetogenic 
T cells in a functional state allowing the transfer of diabetes. 
Sublethal irradiation of transient recipients was used to create 
space in lymphoid tissues for transferred diabetogenic T cells. 
The kinetics of loss of the capacity to transfer diabetes was 
somewhat similar to that of memory helper T cells from rats 
primed with the DNP-KLH hapten-carrier  complex in the 
absence of antigen  (48).  The recurrence of insulitis within 
syngeneic islets grafted under the kidney capsule of/5 cell- 
deprived mice indicates  that  the absence of/5 cell did not 
induce resistance to insulitis  once islet antigens  were rein- 
troduced.  However, the slow recurrence of insulitis within 
grafted islets suggests that the whole autoimmune reaction 
developed as a slow process after grafting  as that  observed 
spontaneously in  the NOD  strain. 
Similar  observations  have  been reported  in  obese strain 
chickens at the level of B cell activation. The production of 
antithyroglobulin autoantibodies is not observed in thyroidec- 
tomized animals  and requires immunization with exogenous 
thyroglobulin to be triggered (49).  The functional status of 
the thyroid or of the islets of Langerhans  is critical in the 
development of thyroiditis and diabetes, respectively.  The di- 
etary iodine  content modulates  thyroiditis  in  obese strain 
chickens (50). Glucose or exogenous insulin reduce as well 
the incidence of diabetes in the BB rat and in the NOD mouse, 
possibly relating to altered islet function or antigen expres- 
sion (51-53). Our data bring direct evidence for the require- 
ment of target cells for a T cell-mediated autoimmune pro- 
cess to develop in vivo and show that/5 cells themselves drive 
the anti-/5 cell T cell immune reponse specifically and indepen- 
dently of the other affected organs. 
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